In their study, Smits et al. showed that QuiremScout® is a superior predictor of intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study were published online on the 9th of August 2019 in the European Journal of Nuclear Medicine and Molecular Imaging. With individualized treatment planning becoming increasingly important for patients who are selected for Selective Internal Radiation Therapy (SIRT), accurate pre-treatment activity planning is essential in order to improve the clinical benefit of the therapy.
More accurate pre-treatment activity planning requires to account for each patient’s specific intrahepatic dose distribution. However, as indicated in a number of scientific papers, the widely used Tech-99m-MAA has limited predictive value. This study shows that QuiremScout® is able to more accurately predict intrahepatic dose distribution, and as such may serve as a predictive “biomarker” for a safe and more effective SIRT treatment.
“Previous studies already demonstrated that QuiremScout® is safe in this population and moreover a better predictor for lung shunting than Tech-99m-MAA. As a result, QuiremScout® allows for more accurate SIRT patient selection. Now, our study shows the potential of QuiremScout® to also improve the efficacy of SIRT, by allowing a more accurate and truly personalized pre-treatment activity planning.” says Maarten Smits MD PhD, first author of the article.
QuiremScout® is used for screening of patients that are candidates for SIRT. QuiremScout® is unique, as it is the only CE-marked product on the market for that purpose.
QuiremSpheres® is the only commercially available SIRT product that contains holmium-166 microspheres. Unlike the widely adopted Yttrium-90 microspheres, holmium-166 microspheres can be visualized in low concentrations by means of Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This allows clinicians to quantitatively assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after the radio-embolization procedure.
The full article can be accessed online: DOI: 10.1007/s00259-019-04460-y